Inhibition of the CXCL12/CXCR4 axis prevents periurethral collagen accumulation and lower urinary tract dysfunction in vivo.
Jill A MacoskaZunyi WangJohanna VirtaNicholas ZachariasDale E BjorlingPublished in: The Prostate (2019)
This is the first study to report that obesity-induced lower urinary tract fibrosis and voiding dysfunction can be repressed by antagonizing the activity of the CXCR4 chemokine receptor in vivo. These data suggest that targeting the CXCL12/CXCR4 signaling pathway may be a clinical option for the prevention or treatment of human male LUTD.
Keyphrases
- urinary tract
- signaling pathway
- cell migration
- endothelial cells
- oxidative stress
- high glucose
- metabolic syndrome
- insulin resistance
- type diabetes
- diabetic rats
- weight loss
- epithelial mesenchymal transition
- pi k akt
- induced pluripotent stem cells
- weight gain
- body mass index
- adipose tissue
- mouse model
- drug induced
- pluripotent stem cells
- high fat diet induced
- cell proliferation
- physical activity
- drug delivery
- replacement therapy
- data analysis
- stress induced